Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$4.40
$0.20(4.55%)
At close: 4:00 PM EDT
$4.40
$0.20(4.55%)
Day’s Range― - ―
52-Week Range$4.35 - $18.40
Previous Close$4.6
Volume4.70K
Average Volume (3M)2.40K
Market Cap
$54.02M
Enterprise Value$68.44
Total Cash (Recent Filing)$5.65M
Total Debt (Recent Filing)$741.31K
Price to Earnings (P/E)―
Beta1.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non-dilutive NIH FundingThe $2.03M Phase IIB NIH award provides two years of targeted, non-dilutive R&D capital for cannabinoid work. It reduces near-term financing pressure, validates the platform with a reputable agency, and materially supports preclinical studies that strengthen partner and licensing prospects.
Platform And Pipeline DiversificationAdding engineered cannabinoid analogs alongside the NCT program diversifies technical and commercial exposure. Scalable, cell-free production of rare cannabinoids can address supply constraints, increase partner appeal, and create multiple value paths beyond a single program over the medium term.
Demonstrated Public Capital AccessRepeated successful public offerings show the company can tap public markets for financing, delivering multi-million dollar proceeds to advance R&D and commercialization. Reliable access to institutional capital supports program continuity and execution while the business remains pre-revenue.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-commercial and has materially widened losses, which continuously depletes equity and increases dependence on external funding. Without near-term revenue inflection, persistent losses raise execution risk and constrain strategic flexibility for 2–6 months and beyond.
Heavy, Persistent Cash BurnSustained negative operating and free cash flow shortens runway and forces management to prioritize financing over organic investment. Persistent cash burn increases the probability of dilutive financings and limits the company’s ability to self-fund development or scale operations in the medium term.
Equity Erosion And Warrant-driven Dilution RiskA sharply reduced equity base combined with frequent offerings and reset-enabled warrants creates significant future dilution risk. These structures can materially dilute shareholders if triggered, complicate long-term investor alignment, and may raise cost-of-capital for subsequent financings.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $4.35 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
eXoZymes’s market cap is $54.02M.
When is eXoZymes’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were eXoZymes’s earnings last quarter?
Currently, no data Available
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 9,281,359 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
eXoZymes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Company Description
eXoZymes
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
EXOZ Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
15.59% Insiders
0.45% Mutual Funds
― Other Institutional Investors
83.27% Public Companies and
Individual Investors